MATWIN’s platform objectives
MATWIN (Maturation & Accelerating Translation With Industry) is the only French open-innovation platform specifically dedicated to oncology. MATWIN, a wholly owned subsidiary of Unicancer group (gathering all the French Comprehensive Cancer Centres) offers several actions (expertise, accelerating program, events, etc.) aiming at accelerating the development of innovative projects dedicated to the fight against cancer.
Research
Strenghten innovations’ transfer potential in partnership with the national ecosystem (canceropôles, TTOs, clusters …
Industry
Mutualize a sourcing platform of « shortlisted » early innovative projects
Patients
Contribute to accelerate treatments/ diagnostics outlooks
How to work with MATWIN ?
MATWIN in figures
supported projects
projects interviewed by the board
start-up created
projects transferred
MEET2WIN participants
MEET2WIN : our annual partnering convention dedicated to open innovation in oncology
News
PDC*line Pharma completes enrolment of four cohorts of patients in PDC-LUNG-101 phase I/II clinical trial
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today [...]
In’CaRe: Call for projects in Oncology and Hematology
Cancers are still a major public health issue. Promoting innovation in oncology in France therefore remains a priority. AstraZeneca demonstrates [...]